© 2023 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#Merck

calendar pages
Gilead and Merck to Collaborate on Next-Generation Long-Acting HIV Treatment
FDA Approved stamp
FDA OKs Delstrigo and Pifeltro
United States of America map with state names
$7M HIV Initiative to Help Underserved People in the Southeast
A scene from NMAC's roundup of Day 1 at #2023USCHA

Highlights From the 2023 U.S. Conference on HIV/AIDS

#2023USCHA was a Love Letter to Black Women—and a joyous family reunion for the HIV community. [VIDEOS]

Merck Will Study Lower Dose of Long-Acting Islatravir

The company will resume development of islatravir for HIV treatment but abandons monthly oral PrEP.

Treatment: Islatravir on Hold

Islatravir, a long-acting antiretroviral, has hit a snag after clinical trial participants experienced falling white blood cell counts.

Cancer Immunotherapy Flushes HIV Out of Hiding

Keytruda can activate T cells that harbor latent HIV, a possible step toward a functional cure.

Long-Acting HIV Therapy Hits a Snag

Studies of islatravir are put on hold after participants experience declining CD4 and lymphocyte counts.
House Speaker Nancy Pelosi receives the first-ever lifetime achievement award during USCHA 2021.

16 Images That Recap the 2021 U.S. Conference on HIV/AIDS

#2021USCHA—the U.S. Conference on HIV/AIDS—may have ended, but you can still experience it via these pics, tweets and videos.
Molnupiravir capsules (Merck)

Oral Antiviral Drug Cuts COVID-19 Hospitalization [UPDATED]

Molnupiravir reduces severe illness and death, but it must be started within days after developing symptoms.
Johnson & Johnson/Janssen COVID-19 vaccine

J&J COVID-19 Vaccine Is 72% Effective After a Single Dose in U.S. Study

Another vaccine, from Novavax, was 89% effective in a U.K. trial, but both were less potent against the South African coronavirus mutation.

Islatravir-Based Treatment Shows Promise

The HIV regimen failed only a few study participants.
Generic image

islatravir

Deondre Moore promotes peer and community HIV education and prevention.

Ensuring Young, Black Communities Know the Transformative Message of U=U

AIDS United speaks with Deondre Moore about promoting U=U among African Americans via the “Owning HIV” campaign.
Yonce Jones of Harlem United will participate in the virtual panel discussion “HIV in Young, Black America.”

How Well Do Black Young Adults Understand HIV and U=U?

Survey findings from the “Owning HIV” campaign show the need for proactive education.

Treatment: Weekly Treatment?

MK-8507, a long-acting NNRTI, will be tested in a weekly regimen with islatravir.

Switching HIV Treatment to Delstrigo Is Safe and Effective

This is according to a three-year study in which people switched from a stable HIV regimen to Delstrigo.

Islatravir-Based HIV Regimen Fails Few Study Participants

None of the people who experienced virologic failure on regimens containing the experimental drug had a viral load of 200 or higher.

Islatravir Plus Pifeltro Shows Promise as 2-Drug HIV Regimen

A mid-stage trial showed the combo suppressed HIV, was well tolerated and resulted in a low rate of virologic failure.
Advertisement
Science News
Features

POZ uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. Our Privacy Policy

Manage

POZ uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. By remaining on our website, you indicate your consent to our Privacy Policy and our Cookie Usage.